Who Owns Inhibikase Therapeutics Stock?
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 91.61%
- Held by insiders
- 6.50%
- Institutional holders
- 142
- Institutions 91.6%
- Insiders 6.5%
- Public and other 1.9%
Who owns Inhibikase Therapeutics stock?
Institutional investors own about 91.6% of Inhibikase Therapeutics's shares, spread across 142 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.50% of IKT.
The largest institutional holders are Sands Capital Alternatives, LLC (9.28%), Soleus Capital Management, L.P. (7.75%) and Trails Edge Capital Partners, LP (6.45%). Together, the top 10 institutions control 56.9% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their IKT positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of IKT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Sands Capital Alternatives, LLC | 13.02M | 9.28% | 0.0% |
| Soleus Capital Management, L.P. | 10.88M | 7.75% | 0.0% |
| Trails Edge Capital Partners, LP | 9.05M | 6.45% | +12.3% |
| Fairmount Funds Management LLC | 8.63M | 6.15% | 0.0% |
| Blackrock Inc. | 8.56M | 6.11% | +10.3% |
| Adar1 Capital Management, LLC | 7.39M | 5.27% | +11.8% |
| Blackstone Inc | 5.94M | 4.23% | 0.0% |
| Siren, L.L.C. | 5.85M | 4.17% | 0.0% |
| Commodore Capital Lp | 5.40M | 3.85% | 0.0% |
| Vanguard Capital Management LLC | 5.05M | 3.60% | +2.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of IKT
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.76M | 2.68% |
| iShares Trust-iShares Russell 2000 ETF | 3.47M | 2.48% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.33M | 0.95% |
| iShares Trust-iShares Russell 2000 Value ETF | 1.30M | 0.93% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.06M | 0.75% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 694.50K | 0.50% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 459.23K | 0.33% |
| iShares Trust-iShares Micro-Cap ETF | 452.65K | 0.32% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 294.00K | 0.21% |
| Quantitative Master Series LLC-Master Small Cap Index Series | 236.79K | 0.17% |
Frequently asked questions
Who is the largest shareholder of Inhibikase Therapeutics?
Sands Capital Alternatives, LLC is the largest institutional shareholder of IKT, owning 9.28% of shares outstanding (13.02M shares) as of its latest 13F filing.
What percentage of Inhibikase Therapeutics is owned by institutions?
Institutions own about 91.6% of IKT shares and 98.0% of the public float.
How much of Inhibikase Therapeutics do insiders own?
Insiders, such as officers and directors, own about 6.50% of IKT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.